[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News & Perspectives
December 1, 1999

New Class of Anti-HIV Drugs

Author Affiliations

Not Available

Not Available

JAMA. 1999;282(21):1994. doi:10.1001/jama.282.21.1994-JMN1201-3-1

San Francisco—While state-of-the-art combination antiretroviral therapy has had an enormous impact in extending and improving the lives of patients with HIV infection, clinicians are increasingly faced with the question of how to help patients who fail to respond to standard anti-HIV drugs because of emerging resistance or other factors. One strategy being pursued by researchers, with the hope of buying time for such patients, is the development of a class of drugs called fusion inhibitors.